Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study in patients with schizophrenia is designed to provide preliminary evidence of the
safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2
doses of EVP-6124 compared with placebo when given with the patient's usual antipsychotic
medication.